Chantal Visser
A5026347571- COVID-19 Clinical Research Studies
- Venous Thromboembolism Diagnosis and Management
- Heparin-Induced Thrombocytopenia and Thrombosis
- Atrial Fibrillation Management and Outcomes
- Long-Term Effects of COVID-19
- Dermatological and COVID-19 studies
- Platelet Disorders and Treatments
- Blood properties and coagulation
- Blood groups and transfusion
- Cancer Treatment and Pharmacology
- COVID-19 and healthcare impacts
- Health Systems, Economic Evaluations, Quality of Life
- Antiplatelet Therapy and Cardiovascular Diseases
- Advanced Text Analysis Techniques
- Cardiovascular Disease and Adiposity
- Palliative Care and End-of-Life Issues
- Cancer survivorship and care
- Diagnosis and Treatment of Venous Diseases
- Heart Failure Treatment and Management
- Radiomics and Machine Learning in Medical Imaging
- Immunotherapy and Immune Responses
- vaccines and immunoinformatics approaches
- Acute Myocardial Infarction Research
- Climate Change and Health Impacts
- Erythropoietin and Anemia Treatment
Erasmus MC
2020-2025
Erasmus University Rotterdam
2023-2025
University Medical Center Utrecht
2022
Maasstad Ziekenhuis
2020
Ludwig Cancer Research
2005
IntroductionIn the first wave, thrombotic complications were common in COVID-19 patients. It is unknown whether state-of-the-art treatment has resulted less second wave.MethodsWe assessed incidence of and overall mortality patients admitted to eight Dutch hospitals between September 1st November 30th 2020. Follow-up ended at discharge, transfer another hospital, when they died, or on 2020, whichever came first. Cumulative incidences estimated, adjusted for competing risk death. These...
Immune thrombocytopenia (ITP) is an acquired autoimmune disorder that characterized by low platelet count and increased bleeding risk. COVID-19 vaccination has been described as a risk factor for de novo ITP, but the effects of in patients with ITP are unknown. We aimed to investigate on count, complications, exacerbation (≥50% decline or nadir < 30 × 109/L >20% decrease from baseline, use rescue therapy). Platelet counts healthy controls were collected immediately before 1 4 weeks after...
Background: Data on risks and benefits of long-term anticoagulants in patients with a life-limiting disease are limited. This cohort study aims to describe (dis)continuation incidences bleeding thromboembolic events vitamin K antagonist (VKA) users disease. Methods: from five Dutch anticoagulation clinics were linked data Statistics Netherlands the Cancer registry. Prevalent VKA diagnosed pre-specified between 01/01/2013 31/12/2019 included followed until 31/12/2019. Hospitalization used...
Thrombotic complications are common in Coronavirus disease 2019 (COVID-19) patients, with pulmonary embolism (PE) being the most frequent. Randomised trials have provided inconclusive results on optimal dosage of thromboprophylaxis critically ill COVID-19 patients. We utilized data from multicentre CAPACITY-COVID patient registry to assess effect differential application Low Molecular Weight Heparin (LMWH) dose protocols PE and in-hospital mortality risk An instrumental variable analysis was...
Epidemiology of pulmonary embolism (PE) may have shifted since the coronavirus disease 2019 (COVID-19) pandemic. This study aimed to describe temporal trends in PE epidemiology Netherlands 2015. Using nationwide data from Statistics Netherlands, all Dutch inhabitants (>16 million) without a history were dynamically identified on 1 January each year assemble eight cohorts PE-free 2015-22. They individually followed until end that respective determine 1-year risk (identified by hospital...
The Fourth Maastricht Consensus Conference on Thrombosis included the following themes. Theme 1: "coagulome" as a critical driver of cardiovascular disease. Blood coagulation proteins also play divergent roles in biology and pathophysiology, related to specific organs, including brain, heart, bone marrow, kidney. Four investigators shared their views these organ-specific topics. 2: Novel mechanisms thrombosis. Mechanisms linking factor XII fibrin, structural physical properties, contribute...
Even though antithrombotic therapy has probably little or even negative effects on the well-being of people with cancer during their last year life, deprescribing at end life is rare in practice. It often continued until death, possibly resulting excess bleeding, an increased disease burden and higher healthcare costs.The SERENITY consortium comprises researchers clinicians from eight European countries specialties different clinical fields, epidemiology psychology. will use a comprehensive...
Background In January 2021, the Dutch vaccination program against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was started. Clinical studies have shown that systemic reactions occur in up to 50% of vaccine recipients. Therefore, COVID-19 could affect anticoagulation control, potentially leading an increased risk thrombotic events and bleeding complications. Aims This article investigates whether BNT162b2 affects control outpatients using vitamin K antagonists (VKAs). Methods...
Thrombosis is a frequent and severe complication in patients with coronavirus disease 2019 (COVID-19) admitted to the intensive care unit (ICU). Lupus anticoagulant (LA) strong acquired risk factor for thrombosis various diseases frequently observed COVID-19. Whether LA associated COVID-19 currently unclear.To investigate if critically ill COVID-19.The presence of other antiphospholipid antibodies was assessed ICU. determined dilute Russell's viper venom time (dRVVT) LA-sensitive activated...
Severe acute respiratory syndrome coronavirus 2 infection is associated with an increased incidence of thrombosis.By studying the fibrin network structure disease 2019 (COVID-19) patients, we aimed to unravel pathophysiological mechanisms that contribute this risk thrombosis. This may optimal prevention and treatment COVID-19 related thrombosis.In case-control study, collected plasma samples from intensive care unit (ICU) patients COVID-19, without confirmed thrombosis, between April...
Abstract Background Fibrinogen variants as a result of alternative messenger RNA splicing or protein degradation can affect fibrin(ogen) functions. The levels these might be altered during coronavirus disease 2019 (COVID-19), potentially affecting severity the thrombosis risk. Aim To investigate fibrinogen in plasma patients with COVID-19. Methods In this case-control study, we measured functional using Clauss assay. Enzyme-linked immunosorbent assays were used to measure antigen total,...
This population-based cohort study aimed to describe changes in incidence of cardiovascular disease (CVD) hospital diagnoses during the COVID-19 pandemic The Netherlands compared with pre-pandemic period. We used Dutch nationwide statistics about hospitalizations estimate rate ratios (IRR) CVD first and second waves 2020 versus same periods 2019. Compared 2019, a diagnosis ischemic stroke (IRR 0.87; 95% CI 0.79-0.95), major bleeding 0.74; 0.68-0.82), atrial fibrillation 0.73; 0.65-0.82),...
Background and ObjectivesFor patients receiving end-of-life care, adjusting polypharmacy deprescription of potentially harmful medicines are important impactors on quality-of-life. Antithrombotic therapies (ATT) used by 30-50% with cancer, rising to 80% in older cancer patients, often continued until a quality-of-life-impacting bleeding event, or patient is physically unable take oral medication. We aimed describe the use ATT occurrence clinical outcomes during care. ApproachLinked health...
Hypercoagulation is one of the most distinct prognostic factors patients with COVID-19 and has been associated arterial thrombosis other venous thrombotic events (VTE). Bleeding complications are far less encountered. The International Society on Thrombosis Haemostasis (ISTH) guidance advises giving prophylactic low-molecular-weight heparin (LMWH) to prevent these events, although there evidence that incidence remains high despite using LMWH. We describe three cases pneumonia were admitted...
The European Medicine Agency has authorized COVID-19 vaccination in adolescents and young adults (AYAs) from 12 years onwards. In elderly vitamin K antagonist (VKA) users, been associated with an increased risk of supra- subtherapeutic INRs. Whether this association is also observed AYAs using VKA unknown. Our aim was to describe the stability anticoagulation after AYA users.A case-crossover study performed a cohort (12-30 years) VKAs. most recent INR results before vaccination, reference...
Background: The European Medicine Agency has authorized COVID-19 vaccination in young adults from 12 years onwards. In elderly vitamin K antagonist (VKA) users, been associated with an increased risk of supra- and subtherapeutic INRs. Whether this is also observed adolescents (AYA) using VKA unknown. Our aim was to describe the stability anticoagulation after AYA users.Materials Methods: A case-crossover study performed a cohort AYAs (12-30 years) VKAs. most recent INR results before...
Abstract Thrombotic complications are common in Coronavirus disease 2019 (COVID-19) patients, with pulmonary embolism (PE) being the most frequent. Randomised trials have provided inconclusive results on optimal dosage of thromboprophylaxis critically ill COVID-19 patients. We utilized data from multicentre CAPACITY-COVID patient registry to assess effect differential application Low Molecular Weight Heparin (LMWH) dose protocols PE and in-hospital mortality risk An instrumental variable...